278 related articles for article (PubMed ID: 22003817)
1. Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold.
Ishikawa T; Seto M; Banno H; Kawakita Y; Oorui M; Taniguchi T; Ohta Y; Tamura T; Nakayama A; Miki H; Kamiguchi H; Tanaka T; Habuka N; Sogabe S; Yano J; Aertgeerts K; Kamiyama K
J Med Chem; 2011 Dec; 54(23):8030-50. PubMed ID: 22003817
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of pyrrolo[3,2-d]pyrimidine human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors: exploration of novel back-pocket binders.
Kawakita Y; Banno H; Ohashi T; Tamura T; Yusa T; Nakayama A; Miki H; Iwata H; Kamiguchi H; Tanaka T; Habuka N; Sogabe S; Ohta Y; Ishikawa T
J Med Chem; 2012 Apr; 55(8):3975-91. PubMed ID: 22439974
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of pyrrolo[3,2-d]pyrimidine HER2/EGFR dual inhibitors: improvement of the physicochemical and pharmacokinetic profiles for potent in vivo anti-tumor efficacy.
Kawakita Y; Miwa K; Seto M; Banno H; Ohta Y; Tamura T; Yusa T; Miki H; Kamiguchi H; Ikeda Y; Tanaka T; Kamiyama K; Ishikawa T
Bioorg Med Chem; 2012 Oct; 20(20):6171-80. PubMed ID: 22980219
[TBL] [Abstract][Full Text] [Related]
4. Surmounting the resistance against EGFR inhibitors through the development of thieno[2,3-d]pyrimidine-based dual EGFR/HER2 inhibitors.
Milik SN; Abdel-Aziz AK; Lasheen DS; Serya RAT; Minucci S; Abouzid KAM
Eur J Med Chem; 2018 Jul; 155():316-336. PubMed ID: 29902719
[TBL] [Abstract][Full Text] [Related]
5. Design and Synthesis of 4-Anilinothieno[2,3-d]pyrimidine-Based Compounds as Dual EGFR/HER-2 Inhibitors.
Abd El Hadi SR; Lasheen DS; Hassan MA; Abouzid KA
Arch Pharm (Weinheim); 2016 Nov; 349(11):827-847. PubMed ID: 27734525
[TBL] [Abstract][Full Text] [Related]
6. Novel C-5 aminomethyl pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases.
Mastalerz H; Chang M; Gavai A; Johnson W; Langley D; Lee FY; Marathe P; Mathur A; Oppenheimer S; Tarrant J; Tokarski JS; Vite GD; Vyas DM; Wong H; Wong TW; Zhang H; Zhang G
Bioorg Med Chem Lett; 2007 May; 17(10):2828-33. PubMed ID: 17368025
[TBL] [Abstract][Full Text] [Related]
7. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
8. Novel pyrrolo[2,1-f][1,2,4]triazin-4-amines: Dual inhibitors of EGFR and HER2 protein tyrosine kinases.
Fink BE; Norris D; Mastalerz H; Chen P; Goyal B; Zhao Y; Kim SH; Vite GD; Lee FY; Zhang H; Oppenheimer S; Tokarski JS; Wong TW; Gavai AV
Bioorg Med Chem Lett; 2011 Jan; 21(2):781-5. PubMed ID: 21177105
[TBL] [Abstract][Full Text] [Related]
9. Structural and energetic basis for the molecular recognition of dual synthetic vs. natural inhibitors of EGFR/HER2.
Bello M; Saldaña-Rivero L; Correa-Basurto J; García B; Sánchez-Espinosa VA
Int J Biol Macromol; 2018 May; 111():569-586. PubMed ID: 29329808
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of novel EGFR/HER2 dual inhibitors bearing a oxazolo[4,5-g]quinazolin-2(1H)-one scaffold.
Yin S; Tang C; Wang B; Zhang Y; Zhou L; Xue L; Zhang C
Eur J Med Chem; 2016 Sep; 120():26-36. PubMed ID: 27187856
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
Smaill JB; Palmer BD; Rewcastle GW; Denny WA; McNamara DJ; Dobrusin EM; Bridges AJ; Zhou H; Showalter HD; Winters RT; Leopold WR; Fry DW; Nelson JM; Slintak V; Elliot WL; Roberts BJ; Vincent PW; Patmore SJ
J Med Chem; 1999 May; 42(10):1803-15. PubMed ID: 10346932
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological activity of N
Kurup S; McAllister B; Liskova P; Mistry T; Fanizza A; Stanford D; Slawska J; Keller U; Hoellein A
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):74-84. PubMed ID: 29115879
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and evaluation of 5-methyl-4-phenoxy-5H-pyrrolo[3,2-d]pyrimidine derivatives: novel VEGFR2 kinase inhibitors binding to inactive kinase conformation.
Oguro Y; Miyamoto N; Okada K; Takagi T; Iwata H; Awazu Y; Miki H; Hori A; Kamiyama K; Imamura S
Bioorg Med Chem; 2010 Oct; 18(20):7260-73. PubMed ID: 20833055
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of pyrimidine-based dual inhibitors of human epidermal growth factor receptor 1 (HER-1) and HER-2 tyrosine kinases.
Cha MY; Lee KO; Kang SJ; Jung YH; Song JY; Choi KJ; Byun JY; Lee HJ; Lee GS; Park SB; Kim MS
J Med Chem; 2012 Mar; 55(6):2846-57. PubMed ID: 22372864
[TBL] [Abstract][Full Text] [Related]
15. New C-5 substituted pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases.
Mastalerz H; Chang M; Chen P; Dextraze P; Fink BE; Gavai A; Goyal B; Han WC; Johnson W; Langley D; Lee FY; Marathe P; Mathur A; Oppenheimer S; Ruediger E; Tarrant J; Tokarski JS; Vite GD; Vyas DM; Wong H; Wong TW; Zhang H; Zhang G
Bioorg Med Chem Lett; 2007 Apr; 17(7):2036-42. PubMed ID: 17270437
[TBL] [Abstract][Full Text] [Related]
16. 2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity.
Ott GR; Wells GJ; Thieu TV; Quail MR; Lisko JG; Mesaros EF; Gingrich DE; Ghose AK; Wan W; Lu L; Cheng M; Albom MS; Angeles TS; Huang Z; Aimone LD; Ator MA; Ruggeri BA; Dorsey BD
J Med Chem; 2011 Sep; 54(18):6328-41. PubMed ID: 21859094
[TBL] [Abstract][Full Text] [Related]
17. Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity.
Hossam M; Lasheen DS; Ismail NSM; Esmat A; Mansour AM; Singab ANB; Abouzid KAM
Eur J Med Chem; 2018 Jan; 144():330-348. PubMed ID: 29275232
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases.
Xu G; Searle LL; Hughes TV; Beck AK; Connolly PJ; Abad MC; Neeper MP; Struble GT; Springer BA; Emanuel SL; Gruninger RH; Pandey N; Adams M; Moreno-Mazza S; Fuentes-Pesquera AR; Middleton SA; Greenberger LM
Bioorg Med Chem Lett; 2008 Jun; 18(12):3495-9. PubMed ID: 18508264
[TBL] [Abstract][Full Text] [Related]
19. Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.
Mahboobi S; Sellmer A; Winkler M; Eichhorn E; Pongratz H; Ciossek T; Baer T; Maier T; Beckers T
J Med Chem; 2010 Dec; 53(24):8546-55. PubMed ID: 21080629
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
